Stockscreener 앱 받기
13.71
0.94%
-0.13
시간 외 거래:
13.71
전일 마감가:
$13.84
열려 있는:
$13.74
하루 거래량:
149.83K
Relative Volume:
1.68
시가총액:
$177.00M
수익:
$14.48M
순이익/손실:
$-26.11M
주가수익비율:
-6.0688
EPS:
-2.2591
순현금흐름:
$-23.86M
1주 성능:
+3.79%
1개월 성능:
-0.87%
6개월 성능:
-21.07%
1년 성능:
-25.69%
1일 변동 폭
$13.38
$13.82
1주일 범위
$13.03
$14.07
52주 변동 폭
$12.52
$20.30
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
13.71 | 178.68M | 14.48M | -26.11M | -23.86M | -2.2591 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-02 | 개시 | Alliance Global Partners | Buy |
| 2025-02-28 | 개시 | Craig Hallum | Buy |
| 2024-07-16 | 재확인 | Maxim Group | Buy |
| 2022-12-22 | 개시 | Maxim Group | Buy |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2020-09-23 | 개시 | BTIG Research | Buy |
| 2016-11-28 | 개시 | Aegis Capital | Buy |
| 2016-08-17 | 개시 | Wells Fargo | Outperform |
| 2014-04-16 | 개시 | Oppenheimer | Outperform |
모두보기
Mediwound Ltd 주식(MDWD)의 최신 뉴스
Director of MediWound (NASDAQ: MDWD) trades shares via spouse - Stock Titan
An FDA-approved burn treatment company’s CEO will join a New York fireside chat. - Stock Titan
Precision Trading with Mediwound Ltd. (MDWD) Risk Zones - Stock Traders Daily
MediWound (NASDAQ: MDWD) seller Hess plans $50K, 3,958-share sale - Stock Titan
New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq - benzinga.com
MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.ca
MediWound (MDWD) Q2 2026 Results: The Available Earnings Metric Delivers a Beat in the Current Update; Closing Reaction: The Stock Records a 1.87% Increase in the Current UpdateRevenue Per Share - vinanet.vn
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayNegative Surprise Momentum - dars.gov.et
What is HC Wainwright's Forecast for MediWound Q3 Earnings? - MarketBeat
Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment - TradingView
MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus
Mediwound Ltd (MDWD) Stock News Today - TradingKey
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Moomoo
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - simplywall.st
Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell - MarketBeat
MediWound Q2 2026 Earnings Call: Complete Transcript - Sahm
A Quick Look at Today's Ratings for MediWound(MDWD.US), With a Forecast Between $22 to $36 - Moomoo
MDWD Maintains by Oppenheimer -- Price Target Lowered to $30.00 - GuruFocus
T. Rowe Price Associates (MDWD) discloses 5.0% ownership in Mediwound common stock - Stock Titan
MediWound Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36 - Moomoo
MediWound (MDWD) Earnings Call zu Q2 2026: VALU auf Kurs, Prognose bekräftigt - TradingKey
Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target - TradingView
Q2 2026 Mediwound Ltd Earnings Call Transcript - GuruFocus
Mediwound earnings missed by $0.03, revenue topped estimates - Investing.com Canada
MediWound (NASDAQ:MDWD) Issues Earnings Results - MarketBeat
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record - GuruFocus
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ... - ca.finance.yahoo.com
A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $22 - Moomoo
MediWound Q2 2026 Earnings Call Transcript - MarketBeat
MediWound Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise - Investing.com
Mediwound Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Mediwound Ltd. Reaffirms Revenue Guidance for the Full-Year 2026 - marketscreener.com
MediWound Q2 sales beat estimates; EPS miss widens as R&D rises - scanx.trade
MediWound Ltd. (MDWD) Q2 FY2026 earnings call transcript - Yahoo Finance
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grew - TradingView
MediWound Q2 2026 Results Highlight EscharEx Trial Progress and New NexoBrid BARDA Agreement - TipRanks
MEDIWOUND ($MDWD) Releases Q2 2026 Earnings - Quiver Quantitative
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
MediWound: Q2 Earnings Snapshot - Barchart.com
MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds - TradingView
MediWound (NASDAQ: MDWD) revenue drops in H1 2026 but guidance held - Stock Titan
MediWound's Phase III Wound Trial Targets 216 Patients at About 40 Sites - Stock Titan
Technical Reactions to MDWD Trends in Macro Strategies - Stock Traders Daily
Mediwound Ltd expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Mediwound Ltd (MDWD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediWound (MDWD) Holds Gains: Modest Advance Points to Consolidation Near $14.39Quote Data - dars.gov.et
Mediwound Ltd (MDWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.04%
자본화:
|
볼륨(24시간):